Stock Track | Mirum Pharmaceuticals Plunges 14.18% After-Hours as Q2 Loss Widens, Misses Estimates

Stock Track

Aug 06

Mirum Pharmaceuticals, Inc. (MIRM) shares plummeted 14.18% in after-hours trading on Wednesday, following the release of the company's second-quarter 2026 financial results.

The biopharmaceutical company reported a quarterly loss of $1.06 per share, significantly missing the analyst consensus estimate of a loss of $0.68 per share by 55.88%. This represents a sharp deterioration from the loss of $0.12 per share in the same quarter last year. Net loss widened to $67.23 million, compared to a net loss of $5.86 million a year earlier, as operating expenses surged to $218.78 million from $132.77 million. While total net product sales rose 37.91% to $176.24 million, beating the consensus estimate of $166.12 million, the substantial increase in operating costs and the deeper-than-expected loss overshadowed the revenue growth and triggered a sharp sell-off in extended trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1152352045"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152352045\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152352045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 04:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152352045","market":"sg","top_or_hot":-1,"title":"Stock Track | Mirum Pharmaceuticals Plunges 14.18% After-Hours as Q2 Loss Widens, Misses Estimates","media":"Stock Track","content":"<p>Mirum Pharmaceuticals, Inc. (MIRM) shares plummeted 14.18% in after-hours trading on Wednesday, following the release of the company's second-quarter 2026 financial results.</p><p>The biopharmaceutical company reported a quarterly loss of $1.06 per share, significantly missing the analyst consensus estimate of a loss of $0.68 per share by 55.88%. This represents a sharp deterioration from the loss of $0.12 per share in the same quarter last year. Net loss widened to $67.23 million, compared to a net loss of $5.86 million a year earlier, as operating expenses surged to $218.78 million from $132.77 million. While total net product sales rose 37.91% to $176.24 million, beating the consensus estimate of $166.12 million, the substantial increase in operating costs and the deeper-than-expected loss overshadowed the revenue growth and triggered a sharp sell-off in extended trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mirum Pharmaceuticals Plunges 14.18% After-Hours as Q2 Loss Widens, Misses Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mirum Pharmaceuticals Plunges 14.18% After-Hours as Q2 Loss Widens, Misses Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-06 04:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mirum Pharmaceuticals, Inc. (MIRM) shares plummeted 14.18% in after-hours trading on Wednesday, following the release of the company's second-quarter 2026 financial results.</p><p>The biopharmaceutical company reported a quarterly loss of $1.06 per share, significantly missing the analyst consensus estimate of a loss of $0.68 per share by 55.88%. This represents a sharp deterioration from the loss of $0.12 per share in the same quarter last year. Net loss widened to $67.23 million, compared to a net loss of $5.86 million a year earlier, as operating expenses surged to $218.78 million from $132.77 million. While total net product sales rose 37.91% to $176.24 million, beating the consensus estimate of $166.12 million, the substantial increase in operating costs and the deeper-than-expected loss overshadowed the revenue growth and triggered a sharp sell-off in extended trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRM","symbol_name":"Mirum Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1152352045","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152352045","pubTimestamp":1785962477,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Mirum Pharmaceuticals, Inc. (MIRM) shares plummeted 14.18% in after-hours trading on Wednesday, following the release of the company's second-quarter 2026 financial results.The biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIRM":"Mirum Pharmaceuticals, Inc."},"translate_title":"股票跟踪 | Mirum Pharmaceuticals 第二季度亏损扩大，未达到预期，盘后股价暴跌 14.18%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":1},"content_text":"Mirum Pharmaceuticals, Inc. (MIRM) shares plummeted 14.18% in after-hours trading on Wednesday, following the release of the company's second-quarter 2026 financial results.The biopharmaceutical company reported a quarterly loss of $1.06 per share, significantly missing the analyst consensus estimate of a loss of $0.68 per share by 55.88%. This represents a sharp deterioration from the loss of $0.12 per share in the same quarter last year. Net loss widened to $67.23 million, compared to a net loss of $5.86 million a year earlier, as operating expenses surged to $218.78 million from $132.77 million. While total net product sales rose 37.91% to $176.24 million, beating the consensus estimate of $166.12 million, the substantial increase in operating costs and the deeper-than-expected loss overshadowed the revenue growth and triggered a sharp sell-off in extended trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}